Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Clinical Colorectal Cancer ; 2022.
Article in English | ScienceDirect | ID: covidwho-1803758

ABSTRACT

Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients’ needs, as EORTC Gastrointestinal Tract Cancer Group we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.

3.
Eur J Cancer ; 144: 200-214, 2021 02.
Article in English | MEDLINE | ID: covidwho-987581

ABSTRACT

Neuroendocrine neoplasms (NENs) are a heterogeneous family of uncommon tumours with challenging diagnosis, clinical management and unique needs that almost always requires a multidisciplinary approach. In the absence of guidance from the scientific literature, along with the rapidly changing data available on the effect of COVID-19, we report how 12 high-volume NEN centres of expertise in 10 countries at different stages of the evolving COVID-19 global pandemic along with members of international neuroendocrine cancer patient societies have suggested to preserve high standards of care for patients with NENs. We review the multidisciplinary management of neuroendocrine neoplasms during the COVID-19 pandemic, and we suggest potential strategies to reduce risk and aid multidisciplinary treatment decision-making. By sharing our joint experiences, we aim to generate recommendations for proceeding to other institutions facing the same challenges.


Subject(s)
COVID-19 , Carcinoid Tumor/therapy , Gastrointestinal Neoplasms/therapy , Medical Oncology/standards , Pancreatic Neoplasms/therapy , Thoracic Neoplasms/therapy , Carcinoid Tumor/diagnosis , Consensus , Gastrointestinal Neoplasms/diagnosis , Humans , Pancreatic Neoplasms/diagnosis , Thoracic Neoplasms/diagnosis
4.
Br J Cancer ; 123(5): 709-713, 2020 09.
Article in English | MEDLINE | ID: covidwho-638678

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic epicentre has moved to the USA and Europe, where it is placing unprecedented demands on healthcare resources and staff availability. These service constraints, coupled with concerns relating to an increased incidence and severity of COVID-19 among patients with cancer, should lead to re-consideration of the risk-benefit balance for standard treatment pathways. This is of particular importance to pancreatic cancer, given that standard diagnostic modalities such as endoscopy may be restricted, and that disease biology precludes significant delays in treatment. In light of this, we sought consensus from UK clinicians with an interest in pancreatic cancer for management approaches that would minimise patient risk and accommodate for healthcare service restrictions. The outcomes are described here and include recommendations for treatment prioritisation, strategies to bridge to later surgical resection in resectable disease and factors that modify the risk-benefit balance for treatment in the resectable through to the metastatic settings. Priority is given to strategies that limit hospital visits, including through the use of hypofractionated precision radiotherapy and chemoradiotherapy treatment approaches.


Subject(s)
Betacoronavirus , Consensus , Coronavirus Infections/epidemiology , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/radiotherapy , Pneumonia, Viral/epidemiology , Practice Guidelines as Topic , COVID-19 , Coronavirus Infections/prevention & control , Coronavirus Infections/virology , Humans , Incidence , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Pneumonia, Viral/virology , Quarantine/methods , Risk , SARS-CoV-2 , United Kingdom/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL